Lawrence D Snell

US Patent:

8168402, May 1, 2012

Filed:

Nov 3, 2006

Appl. No.:

12/084306

Inventors:

Boris Tabakoff - Denver CO, US
Lawrence Snell - Aurora CO, US

Assignee:

Lohocla Research Corporation - Aurora CO

International Classification:

G01N 33/567
G01N 31/00
G01N 33/53
A61K 49/00

US Classification:

435 721, 435 71, 435 724, 436 10, 436 15, 436 63, 436811, 436901, 424 92

Abstract:

The present invention relates to compositions and methods for identifying and quantifying platelet proteins that relate to various bodily states. The present invention further provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies.

US Patent:

6962930, Nov 8, 2005

Filed:

Jun 5, 1998

Appl. No.:

09/171697

Inventors:

Boris Tabakoff - Elizabeth IL, US
Lawrence Snell - Aurora CO, US
Paula L. Hoffman - Denver CO, US

Assignee:

Lohocla Research Corporation - Denver CO

International Classification:

A61K031/4706
C07D215/42
A61P025/08
A61P025/22

US Classification:

514313, 546162

Abstract:

Compounds, composition and method for ameliorating alcohol or drug dependency withdrawal syndromes and withdrawal-induced brain damage are disclosed. In particular, a series of N-substituted-4-uredo-5,7-dihalo-2-carboxy quinoline compounds are disclosed having combined properties as antagonists of voltage-sensitive sodium channels (VSNaC) and as selective competitive antagonists at the strychnine-intensive glycine site of N-methyl-D-aspartate (NMDA) receptors. The disclosed compounds prevent or reduce the signs and symptoms of neurohyperexcitability and particularly the neurohyperexcitability associated with withdrawal syndrome manifested by patients upon withdrawal from chronic use of dependence inducing agents (e. g. ethanol, barbiturates, opiates etc. ). The combined actions of the disclosed compound on VSNaC and NMDA receptors also impart properties to these compounds that are important in preventing and reducing excitotoxic neurodegeneration and reducing anxiety without the undesirable CNS depressant side-effects of agents hitherto employed for these purposes.